uti

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Albiglutide TFA (782500-75-8 free base) (Albiglutide TFA) is a long acting GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus (T2DM).

Tyroserleutide (YSL), a small molecular tripeptide isolated from porcine spleen degradation products, inhibits the growth and metastasis of human hepatocellular carcinoma (HCC) both in vitro and in vivo.

Teduglutide acetate, a GLP-2 analogue, maximizes small intestinal mucosal hypertrophy. Teduglutide acetate partially restores small intestinal epithelial function through an altered distribution of claudin-10, facilitating sodium recirculation for Na-coupled glucose transport and water absorption.

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

Mazdutide acetate is a potent co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR), a gastrin-regulating hormone analog.Mazdutide acetate stimulates insulin secretion from mouse pancreatic islets, and can be used in studies of obesity and type 2 diabetes (T2D).

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Cotadutide acetate (MEDI0382 acetate) is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor with EC50 of 6.9 pM and 10.2 pM, respectively.

Pimelautide is a biological response modifier medicine.

Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent GLP-2 receptor (GLP-2R) agonist, effectively reducing fecal output and enhancing intestinal absorption while alleviating small intestine inflammation. It holds potential for researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Mazdutide (IBI-362; LY-3305677) TFA is a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), recognized as a long-acting synthetic oxyntomodulin analog. It demonstrates a favorable safety and tolerability profile and is utilized in research related to obesity and type 2 diabetes (T2D) [1] [2].

Pegapamodutide (LY-2944876), a dual glucagon-GLP-1 receptor agonist, is utilized in research concerning type 2 diabetes and obesity [1].

Survodutide (BI 456906) (TFA) is a dual agonist of the glucagon and glucagon-like peptide 1 (GLP-1) receptors, and Survodutide (TFA) is synonymous with Survodutide[1].

Retatrutide (LY3437943) TFA is a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), with inhibitory activity and EC50 values of 5.79 nM for GCGR, 0.0643 nM for GIPR, and 0.775 nM for GLP-1R, holding potential for obesity research applications [1].

Glepaglutide (ZP1848) acetate is a long-acting glucagon-like peptide-2 (GLP-2) analogue and a potent GLP-2 receptor (GLP-2R) agonist. It significantly reduces fecal output and enhances intestinal absorption while also mitigating inflammation in the small intestine. Glepaglutide acetate is relevant in researching inflammatory bowel disease (IBD) and Crohn’s disease [1] [2] [3].

Hemagglutinin (48-68), the fragment spanning amino acids 48 to 68 of the influenza virus hemagglutinin, has been demonstrated to induce proliferation in peptide-specific T-cell clones [1].

Dulaglutide (LY2189265), a glucagon-like peptide-1 (GLP-1) receptor agonist, is utilized in the study of type 2 diabetes (T2D) [1] [2].

Retatrutide acetate (LY3437943) is a peptide and triple agonist for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), exhibiting potent inhibitory effects on human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM respectively; it is utilized in obesity research [1].

Agouti-related Protein (AGRP) (83-132) Amide (human) is a segment derived from the agouti-related protein (AGRP), abundantly present in the hypothalamus' arcuate nucleus, and functions predominantly as an inverse agonist for the melanocortin-4 receptor (MC4R), thereby promoting food intake [1] [2].

Pemvidutide, a dual GLP-1R/GCGR agonist, significantly lowers body weight, liver fat, and serum lipids, holding promise for non-alcoholic steatohepatitis (NASH) and obesity research [1].

Cotadutide is a dual receptor agonist that modifies the activity of glucagon and glucagon-like peptide-1 (GLP-1).

Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.

Albiglutide fragment is a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).

Tyroserleutide hydrochloride is a small molecule tripeptide isolated from the degradation product of pig spleen, which can inhibit tumor growth in vivo and in vitro.

Teduglutide is a useful organic compound for research related to life sciences. The catalog number is T35337 and the CAS number is 197922-42-2.

Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide, serves as a long-acting GLP-2 analogue promoting intestinal adaptation and linear growth in neonatal piglet models of short bowel syndrome following complete ileum resection [1].

The GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide, a glucagon-like peptide 1 receptor (GLP-1) agonist.

Dapiglutide (ZP7570) is a long-acting dual agonist of both glucagon-like peptide-1 receptor (GLP-1R) and glucagon-like peptide-2 receptor (GLP-2R), with potential applications in short bowel syndrome (SBS) research.

Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.

Utreglutide is a potent glucagon-like peptide-1 (GLP-1) receptor agonist [1].

Agouti-related peptide (AgRP) is a neuropeptide produced in the brain by the AgRP/NPY neuron. It is only synthesized in NPY containing cell bodies located in the ventromedial part of the arcuate nucleus in the hypothalamus. The appetite-stimulating effect

Ecnoglutide (XW003) is a glucagon-like peptide 1 (GLP-1) receptor agonist [1] .

Tyroserleutide TFA, a tripeptide derived from porcine spleen degradation products [1], exhibits antitumor activity in vitro and in vivo [2].

Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (EC50 value of 0.06 nM) used for the treatment of type 2 diabetes.

Partial antigenic glycoprotein

Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum.

Beinaglutide, a recombinant human GLP-1 (rhGLP-1) polypeptide, exhibits nearly complete homology with human GLP-1 (7–36). It demonstrates dose-dependent effects in improving glycemic control, reducing food intake, delaying gastric emptying, and promoting weight loss. This compound shows promise for research into overweight/obesity and nonalcoholic steatohepatitis (NASH) [1] [2].

Mazdutide (IBI-362; LY-3305677), a synthetic oxyntomodulin analog, serves as a glucagon-like peptide-1 (GLP-1R) glucagon receptor (GCGR) co-agonist. Demonstrating safety and tolerability, Mazdutide is utilized in obesity and type 2 diabetes (T2D) research [1] [2].

Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.

Apraglutide (FE 203799 is a synthetic 33-amino acid peptide and long-acting glp-2 analogue.

Teduglutide TFA, a dipeptidyl peptidase IV-resistant glucagon-like peptide-2 (GLP-2) analogue, exhibits trophic effects on the gut mucosa and is used in research related to short bowel syndrome (SBS) and Crohn's disease (CD) [1] [2].

Bamadutide (SAR425899) is a potent dual agonist for the glucagon-like peptide-1 receptor and glucagon receptor, enhancing β-cell function and reducing glucose absorption in vivo, thereby improving postprandial glucose control. This compound has potential applications in type 2 diabetes research [1].